These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38368225)

  • 1. Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data.
    Kochhar S; Assis DN; Mack C; Izurieta HS; Muratori L; Munoz A; Nordenberg D; Gidudu JF; Blau EF; Vierling JM
    Vaccine; 2024 Mar; 42(7):1812-1825. PubMed ID: 38368225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombosis with thrombocytopenia syndrome (TTS) and vaccine-induced immune thrombocytopenia and thrombosis (VITT): Brighton Collaboration case definitions and guidelines for data collection, analysis, and presentation of immunisation safety data.
    Schönborn L; Pavord S; Chen VMY; Pai M; Gwarzo DH; Buttery J; Munoz FM; Tran H; Greinacher A; Law B
    Vaccine; 2024 Mar; 42(7):1799-1811. PubMed ID: 38302339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensorineural hearing loss (SNHL) as an adverse event following immunization (AEFI): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.
    Carol Liu YC; Ibekwe T; Kelso JM; Klein NP; Shehu N; Steuerwald W; Aneja S; Dudley MZ; Garry R; Munoz FM;
    Vaccine; 2020 Jun; 38(30):4717-4731. PubMed ID: 32418788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anosmia: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
    Liu YC; Munoz FM; Izurieta HS; Tamborska AA; Solomon T; Law BJ; Chhabra N
    Vaccine; 2023 Mar; 41(11):1902-1910. PubMed ID: 36775774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombosis and thromboembolism: Brighton collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
    Gollamudi J; Sartain SE; Navaei AH; Aneja S; Kaur Dhawan P; Tran D; Joshi J; Gidudu J; Gollamudi J; Chiappini E; Varricchio F; Law B; Munoz FM
    Vaccine; 2022 Oct; 40(44):6431-6444. PubMed ID: 36150973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
    Munoz FM; Cramer JP; Dekker CL; Dudley MZ; Graham BS; Gurwith M; Law B; Perlman S; Polack FP; Spergel JM; Van Braeckel E; Ward BJ; Didierlaurent AM; Lambert PH;
    Vaccine; 2021 May; 39(22):3053-3066. PubMed ID: 33637387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anaphylaxis: Revision of the Brighton collaboration case definition.
    Gold MS; Amarasinghe A; Greenhawt M; Kelso JM; Kochhar S; Yu-Hor Thong B; Top KA; Turner PJ; Worm M; Law B
    Vaccine; 2023 Apr; 41(15):2605-2614. PubMed ID: 36435707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute respiratory distress syndrome (ARDS) as an adverse event following immunization: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.
    Serazin NA; Edem B; Williams SR; Ortiz JR; Kawade A; Das MK; Šubelj M; Edwards KM; Parida SK; Wartel TA; Munoz FM; Bastero P
    Vaccine; 2021 May; 39(22):3028-3036. PubMed ID: 33583673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study.
    Gold MS; Gidudu J; Erlewyn-Lajeunesse M; Law B;
    Vaccine; 2010 Jun; 28(28):4487-98. PubMed ID: 20434547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.
    Vogel TP; Top KA; Karatzios C; Hilmers DC; Tapia LI; Moceri P; Giovannini-Chami L; Wood N; Chandler RE; Klein NP; Schlaudecker EP; Poli MC; Muscal E; Munoz FM
    Vaccine; 2021 May; 39(22):3037-3049. PubMed ID: 33640145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI).
    Bonhoeffer J; Kohl K; Chen R; Duclos P; Heijbel H; Heininger U; Jefferson T; Loupi E
    Vaccine; 2002 Dec; 21(3-4):298-302. PubMed ID: 12450705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Congenital microcephaly: Case definition & guidelines for data collection, analysis, and presentation of safety data after maternal immunisation.
    DeSilva M; Munoz FM; Sell E; Marshall H; Tse Kawai A; Kachikis A; Heath P; Klein NP; Oleske JM; Jehan F; Spiegel H; Nesin M; Tagbo BN; Shrestha A; Cutland CL; Eckert LO; Kochhar S; Bardají A;
    Vaccine; 2017 Dec; 35(48 Pt A):6472-6482. PubMed ID: 29150052
    [No Abstract]   [Full Text] [Related]  

  • 14. Auto-immune hepatitis following COVID vaccination.
    Rela M; Jothimani D; Vij M; Rajakumar A; Rammohan A
    J Autoimmun; 2021 Sep; 123():102688. PubMed ID: 34225251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small for gestational age: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data.
    Schlaudecker EP; Munoz FM; Bardají A; Boghossian NS; Khalil A; Mousa H; Nesin M; Nisar MI; Pool V; Spiegel HML; Tapia MD; Kochhar S; Black S;
    Vaccine; 2017 Dec; 35(48 Pt A):6518-6528. PubMed ID: 29150057
    [No Abstract]   [Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applicability of selected Brighton Collaboration case definitions in low-resource settings: A prospective hospital-based active surveillance in Addis Ababa, Ethiopia.
    Sintayehu K; Shaum A; Bonger ZT; Dagnachew Zeleke E; Mamo BT; Anito AA; Bekele D; Longley AT; Gashaw H; Alemu A; Degefaw D; Wang SH; Huang WT
    Vaccine; 2024 Oct; 42(24):126079. PubMed ID: 38909000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 vaccine triggered autoimmune hepatitis: case report.
    Mathew M; John SB; Sebastian J; Ravi MD
    Eur J Hosp Pharm; 2023 Sep; 30(5):e27. PubMed ID: 36207131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neonatal infections: Case definition and guidelines for data collection, analysis, and presentation of immunisation safety data.
    Vergnano S; Buttery J; Cailes B; Chandrasekaran R; Chiappini E; Clark E; Cutland C; de Andrade SD; Esteves-Jaramillo A; Guinazu JR; Jones C; Kampmann B; King J; Kochhar S; Macdonald N; Mangili A; de Menezes Martins R; Velasco Muñoz C; Padula M; Muñoz FM; Oleske J; Sanicas M; Schlaudecker E; Spiegel H; Subelj M; Sukumaran L; Tagbo BN; Top KA; Tran D; Heath PT;
    Vaccine; 2016 Dec; 34(49):6038-6046. PubMed ID: 27491687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report.
    Iguchi T; Umeda H; Kojima M; Kanno Y; Tanaka Y; Kinoshita N; Sato D
    Drug Saf; 2021 Nov; 44(11):1209-1214. PubMed ID: 34347278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.